



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Albert P. TSENG, et al.

Examiner: Unassigned

Serial No.: 09/831,744

Art Unit: Unassigned

Filed: May 11, 2001

Docket: 13030

For: PHOSPHOLIPASE INHIBITORS
FOR THE TREATMENT OF CANCER

Dated: July 22, 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

AUG 01 2002

INFORMATION DISCLOSURE STATEMENT

TECH CENTER 1600/2900

Sir:

In accordance with 37 C.F.R §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. World Health Organisation, "World Health Statistics Annual", (1995);
2. Sheng et al., "Journal of Clinical Investigation", 99(9): 2254-2259 (1997);
3. Giovannucci, et al., "Annals of Internal Medicine", 121(4): 241-246 (1994);
4. Marnett, "Cancer Research", 52: 5575-5589 (1992);
5. Thun, et al., The New England Journal of Medicine, 325: 1593-1596 (1991);
6. Marnett, Preventive Medicine, 24: 103-106 (1995);
7. Meade et al., The Journal of Biological Chemistry, 268(9): 6610-6614 (1993);

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on July 22, 2002.
Dated: July 22, 2002

Michelle Mustafa

8. Laneuville, et al., The Journal of Pharmacology and Experimental Therapeutics, 271(2): 927-934 (1994);
9. Gierse, et al., Biochem J., 305: 479-484 (1995);
10. Williams and DuBois , Am. J. Physiol, 270: G393-G400 (1996);
11. Herschmann, Annu. Rev. Biochem, 60: 281-319 (1991);
12. Dennis, The Journal of Biological Chemistry, 269(18): 13057-1060 (1994);
13. Dennis, TIBS 22: 1-2 (1997);
14. Radvanyi, et al., Analytical Biochemistry 177: 103-109 (1989);
15. Seilhamer, et al., J. Biochem., 106: 38-42 (1989); and
16. Needleman and Wunsch, J. Mol. Biol. 48: 443-453 (1970);
17. Giovannucci, et al., N. Engl. J. Med., 333: 609-614 (1995);
18. Nathans, et al, Cold Spring Harbor Symp. Quant. Biol., 53: 893-900 (1988); and
19. Reddy, et al., J. Biol. Chem., 272: 13591-13596 (1997).

Applicants are submitting copies of the above-cited references. All of the above references are in English, therefore, no translations are required.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no petition, certification statement or fee is required.

Consideration of this Information Disclosure Statement is respectfully requested.

Respectfully submitted,



Frank S. DiGiglio
Registration No. 31,346

Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343

FSD:ahs


1642

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.
13030

In Re Application Of: Albert P. TSENG, et al.

JUL 26 2002



P#7

Serial-No.
09/831,744

Filing Date
May 11, 2001

Examiner
Unassigned

Group Art Unit
Unassigned

Title: PHOSPHOLIPASE INHIBITORS FOR THE TREATMENT OF CANCER

RECEIVED

AUG 01 2002

TECH CENTER 1600/2900

37 CFR 1.97(b)

1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

37 CFR 1.97(c)

2. The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
2. a Notice of Allowance under 37 CFR 1.311,

whichever occurs first.

Also submitted herewith is:

- a certification as specified in 37 CFR 1.97(e);

OR

- the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
13030

In Re Application Of: Albert P. TSENG, et al.

JUL 26 2002
PATENT & TRADEMARK OFFICE
U.S. DEPARTMENT OF COMMERCE

Serial No.
09/831,744

Filing Date
May 11, 2001

Examiner
Unassigned

Group Art Unit
Unassigned

Title: PHOSPHOLIPASE INHIBITORS FOR THE TREATMENT OF CANCER

RECEIVED

AUG 01 2002

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

TECH CENTER 1600/2900

- A check in the amount of _____ is attached.
- The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below. A duplicate copy of this sheet is enclosed.
- Charge the amount of _____
- Credit any overpayment.
- Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No.

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on July 22, 2002 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

Signature

Michelle Mustafa

Typed or Printed Name of Person Mailing Correspondence

*This certificate may only be used if paying by deposit account.

Signature

Dated: July 22, 2002

Frank S. DiGiglio, Registration No. 31,346
SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, NY 11530
(516) 742-4343

FSD:ahs

CC: